

Research for Development

Antonella Valeria Penati *Editor*

In-Home Medication

Integrating Multidisciplinary
Perspectives in Design-Driven Pharma
Practices



Fondazione
Politecnico
di Milano

OPEN ACCESS



Springer

Research for Development

Series Editors

Emilio Bartezzaghi, Milan, Italy

Giampio Bracchi, Milan, Italy

Adalberto Del Bo, Politecnico di Milano, Milan, Italy

Ferran Sagarra Trias, Department of Urbanism and Regional Planning, Universitat Politècnica de Catalunya, Barcelona, Barcelona, Spain

Francesco Stellacci, Supramolecular NanoMaterials and Interfaces Laboratory (SuNMiL), Institute of Materials, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Vaud, Switzerland

Enrico Zio, Politecnico di Milano, Milan, Italy, Ecole Centrale Paris, Paris, France

The series Research for Development serves as a vehicle for the presentation and dissemination of complex research and multidisciplinary projects. The published work is dedicated to fostering a high degree of innovation and to the sophisticated demonstration of new techniques or methods.

The aim of the Research for Development series is to promote well-balanced sustainable growth. This might take the form of measurable social and economic outcomes, in addition to environmental benefits, or improved efficiency in the use of resources; it might also involve an original mix of intervention schemes.

Research for Development focuses on the following topics and disciplines:

Urban regeneration and infrastructure, Info-mobility, transport, and logistics, Environment and the land, Cultural heritage and landscape, Energy, Innovation in processes and technologies, Applications of chemistry, materials, and nanotechnologies, Material science and biotechnology solutions, Physics results and related applications and aerospace, Ongoing training and continuing education.

Fondazione Politecnico di Milano collaborates as a special co-partner in this series by suggesting themes and evaluating proposals for new volumes. Research for Development addresses researchers, advanced graduate students, and policy and decision-makers around the world in government, industry, and civil society.

THE SERIES IS INDEXED IN SCOPUS

Antonella Valeria Penati
Editor

In-Home Medication

Integrating Multidisciplinary Perspectives
in Design-Driven Pharma Practices



Editor

Antonella Valeria Penati
Department of Design
Politecnico di Milano
Milan, Italy



ISSN 2198-7300

ISSN 2198-7319 (electronic)

Research for Development

ISBN 978-3-031-53293-1

ISBN 978-3-031-53294-8 (eBook)

<https://doi.org/10.1007/978-3-031-53294-8>

Politecnico di Milano

© The Editor(s) (if applicable) and The Author(s) 2025. This book is an open access publication.

Open Access This book is licensed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The images or other third party material in this book are included in the book's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the book's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

If disposing of this product, please recycle the paper.

Contents

1	Towards In-Home Medication: Medicinal Products as Daily Objects	1
	Antonella Valeria Penati	
Part I Objects of Science: The Pharmaceutical Industry as a Place of Preciseness		
2	Medicine Packaging Legislation and Its Evolution According to Technological Innovation for Better Healthcare Support	37
	Simona Cazzaniga	
3	Primary Medicine Packaging and Quality Control	57
	Elena Piovosi	
4	Pharmaceutical Forms and Primary Packaging: A Glossary	75
	Elena Piovosi	
5	Secondary Packaging of Medicines: Design Processes for the Pharmaceutical Industry	101
	Marcello Mariani	
6	Secondary Packaging and Leaflets: A Glossary	117
	Marcello Mariani	
Part II Prescribing and Dispensing: Accompanying the Patient to the Correct Use of Medicines		
7	Moving the Care Process in the in-Home Context: The Therapeutic Prescription	131
	Carlo Emilio Standoli, Milena Giovanna Guarinoni, and Enrico Morello	
8	Dispensing Medicines: A Necessary Link Between Doctor and Patient	143
	Antonella Valeria Penati	

9	The Future Digital Pharmacological Prescriptions Between Therapy Adherence and Integrated Healthcare Personal Plans	177
	Giuseppe Andreoni	
10	Navigating the Complexities of the OTC Medicine Ecosystem	189
	Elena Caratti	
11	Dealing with Medicines Through Online Platforms and Communities	205
	Carlo Emilio Standoli and Umberto Tolino	
Part III The Daily Life as a Place of Inaccuracy: The Domesticity of Therapy		
12	Medicines as Designed Objects	223
	Silvia Pizzocaro and Antonella Valeria Penati	
13	The In-Home Place of Medications: Perspectives of Domestication	247
	Silvia Pizzocaro	
14	In-Home. Medicinal Treatment as a Learning Process	269
	Antonella Valeria Penati	
15	Use Phenomenologies. Observing the User While Taking Pharmaceutical Therapies	295
	Antonella Valeria Penati	
16	Use Phenomenologies: Oral Solid Forms in Blister Packs	313
	Antonella Valeria Penati	
17	Use Phenomenologies: What Does the User Do with the Secondary Medicine Packaging and Package Leaflet?.	337
	Antonella Valeria Penati	
Part IV The Pharmaceutical Product System: Premises for the Definition of a Repertory of Good Practices		
18	How Political and Cultural Situations Are Impacting Pharma Industries	363
	Annabella Amatulli	
19	Medicinal Products: When Innovation Meets the Patient	379
	Lamberto Dionigi	
20	Pharmaceutical Packaging According to the “Packaging Ethics Charter”	395
	Valeria Bucchetti	

21 Sensory Qualities of the Medicines: From Problems to Proposals	411
Dina Riccò	
22 Compendium: Step Toward Design-Oriented Practices in the Pharma Industry in a Multidisciplinary Perspective	429
Antonella Valeria Penati	
Addendum 1 Regulatory References	519
Addendum 2 Medication Errors Data	523
Addendum 3 The Name of Medicines: LASA Medicines	531
Addendum 4 Methods of User Involvement	543
Addendum 5 Undesirable Effects or Product Defects Reporting Procedures ...	547
References	551

Chapter 9

The Future Digital Pharmacological Prescriptions Between Therapy Adherence and Integrated Healthcare Personal Plans



Giuseppe Andreoni

Abstract The medical prescription is a most used and common tool to deliver clinical instructions for healthcare actions to the patient and among all the clinical actors involved in the process. Today this informative process is implemented by a paper sheet different in each country for format and content. In Italy it contains a limited set of instructions and mainly reports administrative data, so missing the main function to provide information and to act as a *pro-memoria* tool (about therapy parameters like dosage, assumption plan, interactions) for the patients. This is a factor affecting therapeutical adherence and, consequently, efficacy. New digital technologies offer the new e-health services to empower patients, caregivers, and clinical operators in the frame of the 5-P medicine for a more personalized and accurate approach. This process should involve also the first step towards health which is represented by the access to healthcare and the consequent prescription (pharmaceutical or diagnostic or therapeutical). This chapter discusses the current situation of processes driven by medical prescriptions, their formats, and their expected evolution in the frame of the new digital medicine vision.

9.1 Introduction

The medical prescription is a very common tool to deliver clinical instructions for healthcare actions: diagnostic examination, specialistic consultation for diagnosis or rehabilitation, pharmaceutical indication. Its scope is specifically informative, both for the patient and for the final clinical actor: the specialist for the consultation, the pharmacist for the medicine delivery to the patient, the administrative officer and the technical biomedical operator at the hospital for the diagnostic or rehabilitative interventions. The pharmacological therapy represents the most common and diffused healthcare practice in the world, treating both chronic and time-limited

G. Andreoni (✉)

Department of Design, Politecnico di Milano, Milan, Italy

Bioengineering Laboratory, Scientific Institute IRCCS E. Medea, Bosisio Parini, Italy

e-mail: giuseppe.andreoni@polimi.it

© The Author(s) 2025

A. V. Penati (ed.), *In-Home Medication*, Research for Development,

https://doi.org/10.1007/978-3-031-53294-8_9

pathologies. It is generally driven to the patient through a prescription of the general practitioner (GP) for common and low complexity pathologies or of a specialist doctor (SD): the first one verbally explains the assumption mode and frequency and deliver a standard health recipe which the patient goes to the pharmacy with to buy/ receive the medication; the SD provides the report of the visit with the prescription and this is to be asked again to the GP. In some cases, for low complexity and common pathologies a self-medication is also frequent, according to personal experience and symptoms understanding. This common process should be optimized considering the 5P medicine vision (Pravettoni and Triberti 2020), meaning the proposed strategy to improve the clinical efficacy and efficiency in health and economic sense by a Preventive, Predictive, Personalized, Participatory and Pluri-expert approach that leads the process towards the Precision Medicine (Fig. 9.1). In this way we can also try to minimize the impact of the non-adherence to pharmacological therapy thanks to the so-called patient empowerment and her/his active participation to the process (Andreoni et al. 2022).

The correct prescription, at the right time, with the correct medication, for the exact patient, correct dose (personalized vs standard amount in the package), correct dosage (amount per day/week), correct assumption over time (assumption typology and distribution of assumption per day/week), correct duration (medication assumption and washout) is the perfect “pathway to health”. This process and the patient empowerment towards the full understanding of the pathology, of the therapy and of the correct therapeutical plan, need new and more efficient tools for




Fig. 9.1 The evolution of the medicine

the complete communication among and the involved actors (e.g., patient, doctor, pharmacist, nurse, therapist, familiar caregiver, etc.) in the very different paths that could be activated.

9.2 The Medical Prescription

9.2.1 *The Communication in the Medical Prescription*

In pharmaceutical therapies the most common tool is the medical prescription. This process is done by a verbal and written transmission of information from the medical doctor to the patient and or eventually her/his familiar caregiver. Indeed, the correct and complete communication is the first step toward therapy adherence. But Kessels (2003) demonstrated that the verbal component of the process is not sufficient: memory for medical information is often poor and inaccurate, especially when the patient is old or anxious (Kessels 2003) Patients tend to focus on diagnosis-related information and fail to register instructions on treatment. Sinbukhova et al. (2021) recently recorded that patients were able to remember correctly 24.8% of medical information on the next day after consultation by a neurosurgeon on average (Sinbukhova et al. 2021) The main factors affecting the correct communication were anxiety and depression with negative correlation to the level of information assimilated by patients: the higher level of anxiety and depression before surgery led to decrease remembering of medical information by the patients. Their conclusion was that is necessary to increase remembering of medical information by patients because of it is allowing to improve the results of treatment.

Simple and specific instructions are better recalled than general statements (Kessels 2003). The written prescription should complement this process. In fact, patients can be helped to remember medical information by use of explicit categorization techniques. In addition, spoken information should be supported with written or visual material. Visual communication aids are especially effective in low-literacy patients, but again Kessels (2003) found that video or multimedia techniques do not improve memory performance or adherence to therapy. Laws et al. (2018) studied the factors associated with patient recall of key information in ambulatory specialty care visits; their findings showed forty-nine percent of decisions and recommendations were recalled accurately without prompting; 36% recalled with a prompt; 15% recalled erroneously or not at all (Laws et al. 2018) Provider behaviours hypothesized to be associated with patient recall, such as open-questioning and “teach back”, were rare. Findings suggest that patient recall could be enhanced if providers were to use more of the techniques to encourage patient engagement, such as open questioning, agenda setting, and teach-back; and limit the amount of information to be remembered in a single visit based on an assessment of patients’ ability to recall.

9.2.2 The Format of the Medical Prescription

The medical prescription has no common international standard format. Each country has a different situation for information that this medical document shall contain and provide.

For example, in the USA it is a very informative module (Fig. 9.2a) that must include several items (Kenny and Preuss 2022). In the USA there are five different levels of scheduling for medications (I–V), with schedule I, having the tightest controls, and V, being the least restrictive. Schedule II medicines are the highest level of misuse potential medications that may be prescribed by a clinician; these medicines

Labels for Figure 9.2a:

- Pharmacy name and address
- Patient name and address
- Name and strength of drug
- Drug instructions
- Physical description
- Pharmaceutical manufacturer
- Expiration date
- Number of times you can reorder this drug
- Number used by pharmacy to identify your prescription
- Your doctor's name
- Pharmacy phone number
- Date to place your refill order
- Number of pills in bottle
- Date drug was filled by pharmacy
- Pharmacist in charge
- Federal caution state- Date prescription ment

Labels for Figure 9.2b:

- Surname, Name and address of the patient
- Pharmaceutical prescription: name of the medication and its dosage
- Number of boxes
- Reference law
- Patient ID code
- Number of boxes
- Date
- Doctor ID code
- Name of the doctor

Fig. 9.2 Different formats in medical prescription: (a) the version adopted in USA (above) with very detailed contents; (b) the Italian format (below) as simple indication of the pharmaceutical treatment

traditionally were only allowed to be filled by paper prescription but today they are prescribable via electronic prescribing of controlled substances (EPCS). Schedule III-V medications may be prescribed by a clinician via traditional paper prescription, by a verbal order over the phone, or using the EPCS system. Practitioners may still write and sign prescriptions for schedule II-V medications if they choose; verbal orders to the pharmacist are only permitted for schedule III-V medications. In case of EPCS, it should also record the following information in the prescription: name of the pharmacy who is receiving the prescription, its telephone number and address.

In Italy, the medical prescription is a more and administrative ticket (Fig. 9.2b), namely standardized sheet where only simple information is given about the medication to be given to the patient by the pharmacist as prescribed by the doctor (usually the GP or sometimes directly the SD), so missing most of the relevant information. This communication problem is exacerbated in case of polypharmaceutical prescription at the same time. With the increase of aging population this condition is becoming quite common. In Italy, in 2017, Valent (2019) recorded that 63.7% of the general population received at least one medicine prescription, and 25,218 persons were co-prescribed ≥ 5 medications at least once (Valent 2019). The prevalence of co-prescriptions among persons ≥ 65 years was 31.7%. 20,793 persons used ≥ 60 defined daily doses of ≥ 5 medications. The prevalence of all these phenomena was much higher in the elderly than in children and adults. The number of comorbidities significantly affected all types of polypharmacy. We can assume that this situation could be similar in most of the European and western countries with a similar social structure: from this the prevalence of polypharmacy is high, particularly among the elderly.

In the US, the implementation of electronic prescribing has significantly reduced the number of medication errors from a prescription standpoint (legibility, dosage, frequency, etc.) (Kaldy 2016; Volpe et al. 2016). The definition of a set of requirements for the prescriptions was a standpoint. For a pharmacist to dispense a controlled substance, the prescription must include specific information to be considered valid: Date of issue, Patient's name and address, Patient's date of birth, Clinician name, address, DEA number, Medicine name, Medicine strength, Dosage form, Quantity prescribed, Directions for use, Number of refills, Signature of prescriber.

9.2.3 *Adherence to Medical Prescription*

Polypharmacy is one of the most important risk factors for the onset of adverse medicine reactions, with a consequent impact in terms of increased hospital admissions, increased costs, and mortality. The management and the therapy for chronic diseases is a typical example of polypharmacy and poor adherence. Therapy management is even more difficult when the condition is chronic and therefore implies a constant relationship with the disease throughout one's life.

In a specific report of WHO (2003a), the estimate of adherence in patients suffering from chronic diseases is only 50%, in developed countries; while the impact of low adherence in developing countries was assumed to be even higher, given the scarcity of health resources and inequalities in access to health care (Quaderni SIF 2017). For adhesion or adherence to therapy it is meant the active compliance of the patient at doctor's recommendations regarding times, doses, and frequency of intake of the medicine for the entire course of therapy. More adherence means reduced risk of hospitalization, reduced complications associated with the disease and with lower entity, greater safety, and efficacy of treatments and even reduction of costs for therapies.

Even today, data from studies and literature confirm that adherence to chronic therapies remains an emerging and current problem. 80% of people over 65 suffer from heart failure, respiratory insufficiency, sleep disorders, diabetes, obesity, depression, dementia, hypertension, which often occur simultaneously in the same individual (Ministero della Salute 2017). By 2020, chronic diseases will represent about 80% of all diseases in the world, for the management of which about 70–80% of global resources will be committed.

The National Institute for Health and Care Excellence (NICE) with respect to adherence in chronicity, underlines that there is a high risk of error in taking treatments, especially in the presence of polypharmacotherapy and multimorbidity. WHO estimates indicate that between 30% and 50% of prescribed medicines are not taken as they should (WHO 2003a). Additionally, between 30% and 70% of patients make a mistake or inadvertently switch medications, especially when switching from one regimen or treatment area to another. In the guide, NICE underlines the importance of shared decision and the involvement of the person, as an essential component of evidence-based medicine.

A report commissioned by the Department of Health has revealed that in UK between 5% and 8% of unplanned hospital admissions are due to problems related to the use of medicines and, on preventable adverse events that can be attributed to one or more specific errors (Frontier Economics 2014). Therapeutical adherence is also affected by poor communication. Adherence is more detailed defined as:

The degree to which a person's behaviour—in taking medications, following a diet and/or making changes to one's lifestyle—corresponds to the recommendations agreed with health care providers.

This definition considers the attitude of the person to comply with the recommendations of the healthcare professional, in all those behaviours that contribute to full adherence to the treatment path, from pharmacological or follow-up prescriptions, to dietary indications, to suggestions for a change in lifestyle (WHO 2003b). When the communication between the clinician and the patient is imperfect, the latter is exposed to adherence error. Poor adherence produces important impacts both from a clinical point of view, and therefore from the health of the community, but also from the point of view of the sustainability of health systems, a growing problem in many countries. It is in fact the main cause of non-effectiveness of pharmacological therapies and is associated with an increase in healthcare interventions, morbidity,

and mortality, representing damage both for patients and for the healthcare system and for society. Some studies revealed that 30–50% of adults in America do not adequately follow the prescriptions of long-lasting medicines, with waste of about 100 billion dollars a year and the patient at greatest risk of non-adherence is represented by the elderly in polytherapy (Marcum et al. 2013; Iuga and McGuire 2014). The pharmacological prescription for acute problems (antibiotic therapy) is followed by 3/4 of the patients while if the therapy lasts 10 days, only 1/4 of the patients completes the cycle.

Furthermore, these studies confirm that therapeutic non-adherence is particularly critical in patients with long-term therapies and polytherapy, with all the consequences that may derive from a discontinuity of the treatment (compromised efficacy of the therapy) (WHO 2003b). This is very often due to the psychological and emotional condition of the chronic patient which translates into discomfort, loss of trust, demotivation with respect to the efficacy/benefits of the treatment or due to the complexity of managing the therapy.

9.3 The New Model: Towards Territorial and Personalized Healthcare

To achieve Precision Medicine a structural reform of the healthcare system and its services is needed. The pandemic period demonstrated the need of the exploitation of two main elements.

- The Precision Medicine is targeted to the individual patient and for this it requires the deep knowledge of this patient; data are essential but not exhaustive. The prolonged and comprehensive knowledge about the patient's health and history and about the social environment where she/he lives is needed for a global and efficient approach. Only a clinical operator close to the patient can engage with her/him this kind of trusted relationship to have a full diagnostic, therapeutical or rehabilitation adherence. On this the new concept of Clinical Pathways are rapidly being adopted.
- The territorial medicine is the near presence of services and resources available to the patient in her/his own environment or town (Andreoni 2023). These services need a proper management tool to be activated. The medical prescription should evolve to a service enabling tool, integrating all the necessary information to identify all the actions and their parameters for the best delivery of the proper, personalized care intervention. At the same time, a comprehensive and intuitive Electronic Health Record should be developed and available for the recording and the integration of these data, actions, and outcomes, not for administrative purposes but as factors, parameters, and indexes of an individual health model (Kamel Boulos and Zhang 2021).

The Clinical Pathways define the best diagnostic, treatment or rehabilitative process for a specific pathology, or a clinical problem based on the best technical-scientific knowledge and in relation to the available resources. They allow the Healthcare System to outline, the best practicable approach for the best result for the patient and for the optimization of resources within the healthcare organization. The purpose of the clinical pathways is to define a homogeneous, structured, integrated, and multidisciplinary pathway for the management of the pathology/condition being treated, optimize the network of services and trying to meet the needs of patients, ensure during all stages the continuity of care, promote communication and discussion between the professionals involved. They can describe the entire patient care pathway (Diagnostic Therapeutic Assistance Pathway—PDTA) or one or more phases of the path itself (Diagnostic Therapeutic Pathway—PDT; Integrated Care Pathway—PIC), but always providing the integration between hospital and territorial services (Ministero della Salute 2017). Through this structured protocol the healthcare system aims to guarantee: the reproducibility of actions but in a personalized care plan, the indicators needed to monitor the outcomes and clinical and management level, the uniformity of services provided to all patients, the reduction of the extraordinary events; the integration of the clinical service to the patient with shared communication among all the involved actors, the definition of patient management plan with well identified and clear roles for the actors involved in the process and creating awareness and trust in the patient. And awareness and trust mean empowerment of the patient and the adoption of an active role in co-managing her/his own health, the increase the adherence to the clinical actions by the patient and her/his best achievement of therapeutic targets (with lower expenditure). This patient empowerment strategy is struggling to establish itself because it is linked to the relationship with the treating doctor and with health professionals, which should evolve towards a less asymmetrical model, with the patient called to be an increasingly active part in decisions relating to your health. For this reason, in the next future the education of the patient and her/his caregivers represents one of the most important products of the empowerment process.

In this light, and with these premises, the medical prescription sheet should evolve from an administrative document to a service-enabling document, to a tool describing in a complete, comprehensive, and intuitive format the personal Clinical Pathway for a unique and identified subject in a well-defined health environment with its players (GP, SD, other clinical operators, familiar caregivers, etc.).

9.4 The New Health E-Prescription

This process needs to be integrated into the continuous technological evolution of products and services. Today the technology offers connected devices and mobile terminals, multimodal communication, apps and webapps providing several and different services. Also in medicine, this revolution has opened new perspectives to be fully exploited: smartphone and related apps allows access and consultation of the

Electronic Health Record (and of health digital twins which is the new frontier of health data integration), tele-visit, ubiquitous monitoring of health parameters, up to e-administration of clinical events (Kamel Boulos and Zhang 2021).

In this perspective, also the medical prescription must evolve towards a more mature and evolutive format. It has the potentiality to become an active service tool not simply a static administrative ticket. The e-prescription should be co-designed to implement the explicit and implicit needs for a multimodal system for communication, education, reminder, adherence monitoring and other functionalities.

This new e-prescription should be a shared, cloud resident e-document connecting and to be updated by all the actors, each one with the own proper role and different authorization levels: the patient, the GP, the SD, the pharmacist, the rehabilitation operator or the technical for the imaging examination. In other word it should become a single common tool for many services. It is not to be confused with the Electronics Health Record: this is the complete personal health database, while the e-prescription is related and could drive a single, even complex, process. In this way the traditional step-by-step procedure or transfer of the material medical prescription (from the GP to the patient, from the patient to the hospital for the examination or to the pharmacist for the collection of the medicines or to the SD and other options) is translated into a new process, integrated and processed in the cloud and managed by the mobile terminals of the patient, the GP, the pharmacist and so on in relation to the service. To provide a personalized, aware, trusted, and clear process to the patient and her/his familiar caregiver, all the actors should be involved in the co-design process to integrate in this new format the proper information and needed service description with its parameters (for instance, from a simple pharmaceutical prescription to a complex technological examination).

Some possible services that the new e-prescription could enable or embed can be the following suggestions:

- link to multi-media instructions for supporting the correct assumption even for simple situations (even simple but frequent questions like: *can I break the pill before intake? Should I drink only water, or can I drink other liquids?* etc.);
- link to the national pharmaceutical agency and specific webpage, to retrieve all the information about the prescribed medicine, such as active principle, the other ingredients, the possible interactions with other medicines, the different dosages available and any other important recommendations, to maximize adherence and efficacy;
- link to the clinical studies and their full outcomes, pre- and post-market registries of efficacy or adverse events, for a complete awareness about the treatment;
- the generation of a calendar and its download on the mobile device for the complete treatment plan and related reminder;
- the generation of a calendar and its download on the mobile device for examination or rehabilitation sessions;
- link to e-administration services like the procedures and access to online resources for bookings, payments, and other services (GP or Hospital or territorial points).

In this development UX/UI design methodologies could play a very relevant role, supporting access, usability, content readability, intuitive implementation of complex processes of prescription able to avoid errors or misunderstandings that in medicine are so dangerous or increasing adherence that is so necessary.

9.5 Conclusion

The organization of a new healthcare systems and structure after the pandemic emergency is asking the adoption of more efficient and quick tools in the clinical practice and organization. Not only complex task should be redesigned and improved but even starting from the paper-based, static, and poor of information medical prescription is a great kick-off towards the future of healthcare.

The e-prescription shall be integrated in the health information systems: communication is the cornerstone of integrated management and care networks, an indispensable element between the various operators, between the various services, between the different levels (territory/hospital), as well as a central factor of the patient's relationship of trust and his empowerment process. The new technologies available (audio-visual communication, telemedicine, etc.) seem to be able to help facilitate communication and improve assistance in terms of effectiveness and efficiency. The main technological requirement is the interoperability with respect to the various platform and operative systems and its connectivity. The main user requirements are usability and content intuitiveness so to implement an error-free process among all the actors. The main service requirement is the integration so to have a structured continuous process along with the clinical and the administrative procedures. The development of this new format for the medical prescription could be a strategic choice in improving our healthcare services, in saving time, saving costs, increasing efficiency and, above all, the quality of life and our health.¹

References

- Andreoni G (2023) Capsules of health in the city. In: Anzani A, Scullica F (eds) *The city of care*, Springer series in design and innovation, vol 26. Springer, Cham. https://doi.org/10.1007/978-3-031-14608-4_10
- Andreoni G, Caiani EG, Castaldini N (2022) Digital health services through patient empowerment: classification, current state and preliminary impact assessment by health pod systems. *Appl Sci* 12:359. <https://doi.org/10.3390/app12010359>
- Frontier Economics (2014) *Exploring the costs of unsafe care in the NHS: A Report Prepared for the Department of Health*. London. Available online: <https://www.frontier-economics.com/>

¹The author wants to sincerely thank Dr. Erio Morcelli, for the extensive discussion to understand the evolution of the new territorial health scenario, of the introduction of the PDTA with their expected impact, and of the new roles for prescription in the view of a General Practitioner.

- [media/2459/exploring-the-costs-of-unsafe-care-in-the-nhs-frontier-report-2-2-2-2.pdf](#). Last accessed on 15 Jan 2023
- Iuga AO, McGuire MJ (2014) Adherence and health care costs. *Risk Manag Healthc Policy* 7:35–44. <https://doi.org/10.2147/RMHP.S19801>
- Kaldy J (2016) Controlled substances add new layer to E-prescribing. *Consult Pharm* 31(4):200–206
- Kamel Boulos MN, Zhang P (2021) Digital twins: from personalised medicine to precision public health. *J Pers Med* 11(745). <https://doi.org/10.3390/jpm11080745>
- Kenny BJ, Preuss CV (2022) Pharmacy prescription requirements. [Updated 24 Sep 2022]. In: StatPearls [internet]. StatPearls Publishing, Treasure Island. 2023 January. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK538424/?report=classic>
- Kessels RPC (2003) Patients' memory for medical information. *J R Soc Med* 96:219–222
- Laws MB, Lee Y, Taubin T, Rogers WH, Wilson IB (2018) Factors associated with patient recall of key information in ambulatory specialty care visits: results of an innovative methodology. *PLoS One* 13(2):e0191940. <https://doi.org/10.1371/journal.pone.0191940>
- Marcum ZA, Sevick MA, Handler SM (2013) Medication nonadherence: a diagnosable and treatable medical condition. *JAMA* 309(20):2105–2106. <https://doi.org/10.1001/jama.2013.4638>
- Ministero della Salute (2017) Direzione Generale della Programmazione Sanitaria. Piano Nazionale della Cronicità. Available online: https://www.salute.gov.it/imgs/C_17_pubblicazioni_2584_allegato.pdf. Last accessed on 15 Jan 2023
- Pravettoni G, Triberti SA (2020) “P5” approach to healthcare and health technology. In: Pravettoni G, Triberti S (eds) *P5 eHealth: an agenda for the health technologies of the future*. Springer, Cham
- Quaderni della SIF—Società Italiana di Farmacologia (gennaio 2017) Anno XIII n. 42. <https://www.sifweb.org/pubblicazioni/quaderni-della-sif>
- Sinbukhova EV, Shimanskiy VN, Tanyashin SV, Shevchenko KV, Poshataev VK, Abdurakhimov FD, Lubnin AY (2021) Remembering what the doctor said: how much of medical information will the patient remember? *Russ J Neurosurg* 23:50–60. <https://doi.org/10.17650/1683-3295-2021-23-4-50-60>
- Valent F (2019) Polypharmacy in the general population of a Northern Italian area: analysis of administrative data. *Annali Istituto Superiore di Sanità* 55(3):233–239. https://doi.org/10.4415/ANN_19_03_06
- Volpe CR, Melo EM, Aguiar LB, Pinho DL, Stival MM (2016) Risk factors for medication errors in the electronic and manual prescription. *Rev Lat Am Enfermagem* 24:e2742
- World Health Organization (WHO) (2003a) Report on medication adherence, Geneva
- World Health Organization (WHO) (2003b) Adherence to long term therapies: evidence for action, Geneva

Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

